The invention relates to a system (10) for coating powdered raw material, the system comprising: a turbine (12) for rotating a mass of carrier particles (20) in a direction of rotation; a dosing device (14) for introducing at least one powdered raw material (26) into the turbine (12), wherein the dosing device (14) comprises a feed screw (22) having an end (28) configured to be arranged in the mass of carrier particles (20); a spray nozzle (16) for spraying a liquid (32) into the turbine (12), wherein the spray nozzle (16) has an outlet (30) configured to be arranged in the mass of carrier particles (20), and wherein the outlet (30) of the spray nozzle (16) is positioned downstream of the end (28) of the feed screw (22) in the direction of rotation of the mass of carrier particles (20), such that the powdered raw material (26) is mixed by the nozzle delivering the sprayed liquid (32).
B01J 2/12 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes dans des tambours rotatifs
The present invention relates to a process for preparing an orally administered pharmaceutical composition with colonic delivery, comprising at least one core and a coating layer, making it possible to obtain a pharmaceutical composition which exhibits uniform and reproducible dissolution and therefore likewise uniform and reproducible release of the active ingredient with low coefficients of variation, said process being characterized in that it comprises the following steps:
a) Spraying onto a neutral support an aqueous suspension comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 5.5 and at least one active ingredient intended to be delivered in the colon;
or
a′) Spraying onto a neutral support an aqueous suspension comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 5.5 then
b′) Dusting at least one active ingredient intended to be delivered in the colon onto the microgranules obtained after step a′);
c′) carrying out steps a′) and b′) alternately until the desired content of active ingredient has been obtained
and
d) Coating the microgranules obtained after step a) or c′) by spraying a composition comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 6, an anionic (meth)acrylate copolymer that is soluble at a pH greater than 7 and an anionic (meth)acrylate copolymer that is insoluble in an aqueous medium.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Computer software in the field of health; Downloadable computer software applications in the health sector; Artificial intelligence software for healthcare; Software as a medical device [SaMD], downloadable; Diagnostic computer software; Databases. Tools for medical diagnostics, Apparatus and instruments for use in medical diagnosis; Medical apparatus and instruments; Testing apparatus for medical purposes. Scientific and technological services and research and design relating thereto; Scientific laboratory services; Computer software design; Research and development of new products for others; Medical and pharmacological research services; Computer software research; Design and development of medical technology; Development of databases; Maintenance of databases; Conducting technical project studies; Project studies relating to software; Design and development of computer software in the field of health care; Design and development of medical diagnostic apparatus. Medical analysis services and Pharmacological analysis For diagnostic or therapeutic purposes; Medical and healthcare services; Telemedicine services; Medical diagnostic services; Medical evaluation services; Medical information; Providing information, in relation to the following fields: Medical services; Medical and therapeutical services, namely Medical and therapeutic services provided using digital tools.
4.
Low-dosage orodispersible opioid tablet and method for preparing same
A low-dosage orodispersible opioid tablet including: 10 to 30% by weight of opioid granules, and 70% to 90% by weight of a mixture of compression excipients. The granules include 8 to 27% by weight of the opioid and 72% to 93% by weight of a mixture of diluent and binder. The mixture of compression excipients includes at least one disintegrating agent, one diluting agent, one lubricating agent, one permeabilising agent, and optionally a sweetener, a flavouring and/or a colouring, the ratio between the lubricating agent and the permeabilising agent being greater than or equal to 1, the quantity of lubricating agent being 1 to 2% by weight of the tablet, and the quantity of permeabilising agent being 0.5 to 5% by weight of the tablet. Also, the method for preparing same.
The present invention relates to a process for preparing an orally administered pharmaceutical composition with colonic delivery, comprising at least one core and a coating layer, making it possible to obtain a pharmaceutical composition which exhibits uniform and reproducible dissolution and therefore likewise uniform and reproducible release of the active ingredient with low coefficients of variation, said process being characterized in that it comprises the following steps: a) Spraying onto a neutral support an aqueous suspension comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 5.5 and at least one active ingredient intended to be delivered in the colon; or a') Spraying onto a neutral support an aqueous suspension comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 5.5 then b') Dusting at least one active ingredient intended to be delivered in the colon onto the microgranules obtained after step a'); c') carrying out steps a') and b') alternately until the desired content of active ingredient has been obtained, and d) Coating the microgranules obtained after step a) or c') by spraying a composition comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 6, an anionic (meth)acrylate copolymer that is soluble at a pH greater than 7 and an anionic (meth)acrylate copolymer that is insoluble in an aqueous medium.
A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Teaching; Training; Teaching; organising and conducting of conferences, seminars and training workshops, Organising and conducting webinars. Research and development of new technologies, in relation to the following fields: Medicine, Pharmacy; Research and development In the field of galenic innovation; Research and development In the field of medicated solutions; Medical and clinical studies (scientific research for medical purposes); Research and development, for others, of new products in the field of medicine and pharmaceuticals; Engineering services, in relation to the following fields: Medicine, Pharmacy; Chemical research; Chemical analytical examinations.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
Produits et services
Pharmaceuticals; Medical preparations; Veterinary preparations; Sanitary preparations for medical purposes; Foodstuffs and dietetic substances for medical or veterinary purposes; Dietary supplements for animals; Dietary supplements for humans; Cannabis for medical purposes; Medicinal herbs; Medicinal infusions; Medicinal oils. Advertising; Business promotion; Marketing; Providing business information via a web site; Retail services and ON-LINE, in relation the following goods: Pharmaceutical preparations, Medical and veterinary preparations, Sanitary articles, All the aforesaid goods being based on cannabis eye patches for medical purposes.
10.
LOW-DOSAGE ORODISPERSIBLE OPIOID TABLET AND METHOD FOR PREPARING SAME
The invention relates to a low-dosage orodispersible opioid tablet comprising: - 10 to 30% by weight relative to the total weight of the tablet of opioid granules, and - 70% to 90% by weight relative to the total weight of the tablet of a mixture of compression excipients; the granules comprising 8 to 27% by weight relative to the weight of the granules of the opioid and 72% to 93% by weight relative to the weight of the granules of a mixture of diluent and binder, the mixture of compression excipients comprising at least one disintegrating agent, one diluting agent, one lubricating agent, one permeabilising agent, and optionally a sweetener, a flavouring and/or a colouring, the ratio between the lubricating agent and the permeabilising agent being greater than or equal to 1, the quantity of lubricating agent being 1 to 2% by weight relative to the total weight of the tablet, and the quantity of permeabilising agent being 0.5 to 5% by weight relative to the total weight of the tablet, and to the method for preparing same.
The invention relates to a low-dosage orodispersible opioid tablet comprising: - 10 to 30% by weight relative to the total weight of the tablet of opioid granules, and - 70% to 90% by weight relative to the total weight of the tablet of a mixture of compression excipients; the granules comprising 8 to 27% by weight relative to the weight of the granules of the opioid and 72% to 93% by weight relative to the weight of the granules of a mixture of diluent and binder, the mixture of compression excipients comprising at least one disintegrating agent, one diluting agent, one lubricating agent, one permeabilising agent, and optionally a sweetener, a flavouring and/or a colouring, the ratio between the lubricating agent and the permeabilising agent being greater than or equal to 1, the quantity of lubricating agent being 1 to 2% by weight relative to the total weight of the tablet, and the quantity of permeabilising agent being 0.5 to 5% by weight relative to the total weight of the tablet, and to the method for preparing same.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products; medical and veterinary
preparations; sanitary preparations for medical purposes;
dietetic foods and products for medical or veterinary
purposes; baby food; food supplements for humans and
animals; plasters; materials for dressings; material for
stopping teeth and dental wax; disinfectants; preparations
for destroying vermin; fungicides; herbicides.
The present invention relates to granules of active ingredient with double taste masking, wherein the double taste masking is achieved by a hot-melt compound selected from waxes, hydrogenated vegetable oils, fatty acids, mono-, di- and triesters of fatty acids and of glycerol, triglycerides, glycerides, polyoxylglycerides, fatty alcohols, and mixtures thereof, and a thermoplastic polymer that is soluble at a pH less than or equal to 5. The invention also relates to the method for producing these granules and to orodispersible tablets containing these coated granules.
A sustained release oral pharmaceutical form suitable for single daily dose administration has a neutral microgranule coated with a mounting layer of active ingredient and pharmaceutically acceptable binder; and a coating layer of a hydrophobic coating polymer of a non-water soluble cellulose derivative, and at least 20% of inert load in relation to dry weight of hydrophobic coating polymer. The pharmaceutical form has improved resistance to rapid release of active ingredient, particularly in the presence of alcohol.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. clothiapine, diltiazem
17.
GRANULES OF AN ACTIVE SUBSTANCE WITH DOUBLE TASTE-MASKING TECHNIQUE, METHOD FOR THE PRODUCTION THEREOF, AND ORODISPERSIBLE TABLETS CONTAINING SAME
The invention relates to granules of an active substance with a double taste-masking technique, wherein the double taste-masking technique is achieved by a thermofusible compound selected from waxes, hydrogenated vegetable oils, fatty acids, mono-, di- and triesters of fatty acids and glycerol, triglycerides, glycerides, polyoxylglycerides, fatty alcohols, and the mixtures thereof, and a soluble thermoplastic polymer with a pH lower than or equal to 5. The invention also relates to the method for producing said granules and to the orodispersible tablets containing said coated granules.
The present invention relates to an oral and/or buccal composition in the form of a thin film of a pharmaceutically active ingredient weakly soluble in water and gastro-intestinal tract fluids, comprising particles of said active ingredient dispersed in a film-forming polymer, at least 50% by weight of the total weight of the active ingredient having a particle size distribution such that at least 90% of said particles have a size below 1000 nm, preferably less than 800 nm, and even more preferably less than 600 nm, and to the method of preparing that composition and the use thereof.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
19.
Orodispersible tablets obtained by compression molding
Embodiments of the present invention provide an orodispersible tablet having a hardness of 30 to 80 N, and preferably 40 to 75 N, a brittleness less than 1% and preferably less than 0.5%, disintegrating in the mouth within 60 seconds and preferably within 40 seconds, comprising an active ingredient in the form of coated microcrystals or microgranules and a mixture of excipients chosen from a group comprising a diluent, a disintegrant, a sweetener, a binder, a levelling agent, a humectant or wetting agent, a lubricant, a flavoring agent, a dye, and mixtures thereof, said mixture of excipients preferably coming in the form of grains.
The invention relates to a pharmaceutical matrix tablet which can be administered orally once or twice per day with gastro-retentive controlled release of Baclofen.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61P 25/32 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance à l'alcool
The invention relates to a pharmaceutical matrix tablet which can be administered orally once or twice per day with gastro-retentive controlled release of Baclofen.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 25/32 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance à l'alcool
The present invention concerns an oral pharmaceutical formulation made from a microemulsion between an aqueous solution comprising at least one BCS (Biopharmaceutics Classification System) class III active principle and one oily phase comprising an oily vehicle that is self-emulsifiable on contact with water.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations, excluding skincare preparations, acne medications, facial washes and goods in the nature of or for use as skincare preparations, acne medications or facial washes.
The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection.
The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.
The subject matter of the present invention is an orodispersible tablet having a hardness of 30 to 80 N, and preferably 40 to 75 N, a brittleness less than 1% and preferably less than 0.5%, disintegrating in the mouth within 60 seconds and preferably within 40 seconds, comprising an active ingredient in the form of coated microcrystals or microgranules and a mixture of excipients chosen from a group comprising a diluent, a disintegrant, a sweetener, a binder, a levelling agent, a humectant or wetting agent, a lubricant, a flavouring agent, a dye, and mixtures thereof, said mixture of excipients preferably coming in the form of grains, characterised in that said tablet is obtained by a method of compression moulding comprising the following steps; preparing the mixture of recipients by humidification, preferably in the form of grains, having a residual humidity or water level from 0.5% to 7%, preferably from 1% to 5%, and more preferably from 2% to 4%, preparing coated microcrystals or microgranules of the active ingredient, mixing the coated microcrystals or microgranules of the active ingredient and the wet mixture of excipients as prepared above, said mixture of excipients preferably being in the form of grains, potentially adding to the wet mixture for compression, as prepared above, excipients chosen from the group comprising a levelling agent, a lubricant, a flavouring agent, a sweetener, a dye, and mixtures thereof, compressing the mixture for compression prepared above in order to obtain a tablet, potentially drying the tablet thereby contained.
The present invention relates to an oral and/or buccal composition in the form of a thin film of a pharmaceutically active ingredient weakly soluble in water and gastro-intestinal tract fluids, comprising particles of said active ingredient dispersed in a film-forming polymer, at least 50% by weight of the total weight of the active ingredient having a particle size distribution such that at least 90% of said particles have a size below 1000 nm, preferably less than 800 nm, and even more preferably less than 600 nm, and to the method of preparing that composition and the use thereof.
The present invention concerns an oral pharmaceutical formulation made from a microemulsion between an aqueous solution comprising at least one BCS (Biopharmaceutics Classification System) class III active principle and one oily phase comprising an oily vehicle that is self-emulsifiable on contact with water.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical, veterinary and sanitary products; dietetic
substances for medical use, food for babies; plasters,
materials for dressings; material for dental fillings and
dental impressions; disinfectants; products for destroying
vermin; fungicides, herbicides.
The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection.
The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection.
The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products; Pharmaceutical products for the
treatment of all types of addictions and particularly
alcohol dependence or excessive alcohol consumption.
The present invention relates to a method for combating chemical submission, which comprises: putting into solution, in a beverage, a pharmaceutical form comprising an active ingredient and at least 0.05 mg, preferably from 0.2 to 5 mg, even more preferentially from 0.3 to 2 mg of at least one water-soluble colouring agent chosen from: indigocarmine or E 132, erythrosine or E 127, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarine green SS, orange II, tartrazine and Sunset yellow FCF, detecting the pharmaceutical form, said detection being characterized by the immediate change in colour of the beverage; it also relates to the use of said colorant for combating chemical submission, and also to a non-film-coated solid pharmaceutical form comprising said colorant.
The invention relates to a pharmaceutical form for combating chemical submission, comprising an active ingredient and at least one compound which enables immediate modification of the organoleptic characteristics of a beverage into which the pharmaceutical form is introduced, said compound being selected from the group comprising an opacifier, a fluorescent agent, floating particles, particles that are perceptible in the mouth, effervescent microgranules, and mixtures thereof; it also relates to the use of these compounds for combating chemical submission and to a method for combating chemical submission using said pharmaceutical forms.
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
42.
PHARMACEUTICAL FORM FOR COMBATING CHEMICAL SUBMISSION OF A MEDICAMENT
The invention relates to a pharmaceutical form for combating chemical submission, comprising an active ingredient and at least one compound which enables immediate modification of the organoleptic characteristics of a beverage into which the pharmaceutical form is introduced, said compound being selected from the group comprising an opacifier, a fluorescent agent, floating particles, particles that are perceptible in the mouth, effervescent microgranules, and mixtures thereof; it also relates to the use of these compounds for combating chemical submission and to a method for combating chemical submission using said pharmaceutical forms.
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
43.
DIVERSION-RESISTANT MICROGRANULES AND MICROTABLETS
The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered.
The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered.
The invention relates to a novel oral pharmaceutical composition which is resistant to immediate discharge of the dose of active ingredient due to alcohol and which enables a single daily intake.
The invention relates to a novel oral pharmaceutical composition which is resistant to immediate discharge of the dose of active ingredient due to alcohol and which enables a single daily intake.
The present invention relates to an injectable pharmaceutical composition with gelling properties containing: -an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein the organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein: R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups. Its use as a vector for the release of active principles, as well as its process of preparation.
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
48.
Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules
Oral pharmaceutical form containing microgranules for the sustained release of at least one active principle, including a neutral carrier that is insoluble in water or in an alcohol solution, or a neutral carrier rendered insoluble in water or an alcohol solution, comprising at least one first mounting layer containing at least one active principle and optionally a pharmaceutically acceptable binding agent, wherein the whole comprises at least one coating based on at least one hydrophobic polymer.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical products, preparations, substances,
excipients, namely pharmaceutical products pertaining to the
pharmaceutical sector; veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use; disinfectants pertaining to the
pharmaceutical sector; chemical, biochemical and biological
products for medical and veterinary purposes; medical
solutions. Research and development of new technologies in the medical
and pharmaceutical fields; research and development in the
field of galenic innovation; research and development in the
field of medical solutions; medical and clinical studies
(scientific research services for medical purposes);
research and development (for others) in the medical and
pharmaceutical fields; engineering in the medical and
pharmaceutical fields; chemical research; chemical analyses.
The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in tablet form suitable for reducing blood concentration fluctuations of said opioid.
The invention relates to a Limus family immunosuppressive macrolide carrier/material formulation, as well as to an orally administered pharmaceutical composition containing same.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical and veterinary preparations; excipients;
sanitary preparations for medical use; dietetic substances
for medical use; disinfectants; chemical, biochemical and
biological preparations, for medical and veterinary use. Research and development in the pharmaceutical industry,
particularly on technologies for the formation of in vivo
lipidic gel for the controlled release of an active
principle.
53.
PHARMACEUTICAL FORMULATION OF NANONISED FENOFIBRATE
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
54.
PHARMACEUTICAL FORMULATION OF NANONISED FENOFIBRATE
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
55.
ALCOHOL RESISTANT SLOW-RELEASE MICROGRANULE-BASED ORAL PHARMACEUTICAL FORMS
The invention relates to an oral pharmaceutical form containing microgranules for the sustained release of at least one active principle, including a neutral carrier that is insoluble in water or in an alcoholic solution, or a neutral carrier rendered insoluble in water or an alcoholic solution, comprising at least one first mounting layer containing at least one active principle and optionally a pharmaceutically acceptable binding agent, wherein the assembly comprises at least one coating containing at least one hydrophobic polymer.
The invention relates to an oral pharmaceutical form containing microgranules for the sustained release of at least one active principle, including a neutral carrier that is insoluble in water or in an alcoholic solution, or a neutral carrier rendered insoluble in water or an alcoholic solution, comprising at least one first mounting layer containing at least one active principle and optionally a pharmaceutically acceptable binding agent, wherein the assembly comprises at least one coating containing at least one hydrophobic polymer.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical and veterinary products; excipients; sanitary
products for medical purposes; dietetic substances adapted
for medical use; disinfectants; chemical, biochemical and
biological products, for medical and veterinary use. Research and development in the pharmaceutical field,
particularly with regard to tablets which are extremely
hard, difficult to crush, grind, cut or chew.
An orally disintegrating multilayer tablet comprising at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and a pore-forming agent.
The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.
The invention relates to a process for packaging products (5) in wells (2) in a plate (1) formed in a strip (4) and sealed by a cover film (6), comprising the following steps: a well-forming station (103) forms wells (2) in the travelling strip (4); a feeding system (107) fills each well (2) with a product (5) such as a pharmaceutical product in the form of a tablet or hard gelatin capsule; and a well-sealing station (109) seals the filled wells with the travelling cover film (6); the process being characterized in that it comprises, following well formation (2) but prior to each well being filled, the following steps: an incident laser beam marks the wells (2) on the strip (4); and the marked strip is cleaned. The invention also relates to a machine for implementing this process.
B65B 9/04 - Enserrage d'objets les uns à la suite des autres ou de quantités de matériaux, entre bandes se faisant face une bande ou bien les deux comportant des poches pour recevoir les objets ou des quantités de matériaux
B65B 61/02 - Dispositifs accessoires, non prévus ailleurs, opérant sur feuilles, flans, bandes, attaches, réceptacles ou paquets pour perforer, inciser ou appliquer des marques de code ou de dates avant l'emballage
B41M 5/24 - Enregistrement par ablation, p. ex. par brûlage de marquesEnregistrement par étincelle
The present invention relates to an injectable pharmaceutical composition with gelling properties containing : - an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein said organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein : .cndot. R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and .cndot. R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups, Its use as a vector for the release of active principles, as well as its process of preparation.
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
64.
PHARMACEUTICAL COMPOSITION WITH GELLING PROPERTIES CONTAINING A TYROSINE DERIVATIVE
The present invention relates to an injectable pharmaceutical composition with gelling properties containing : - an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein said organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein : • R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and • R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups, Its use as a vector for the release of active principles, as well as its process of preparation.
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
65.
Orodispersible tablets of bitter active principles
The invention concerns coated granules including (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, the pharmacological active principle being complexed by low cation-exchange resin containing carboxylic acid groups (COO″), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of the components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules.
The present invention concerns gastroretentive formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent and process for manufacturing said formulation.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical products, preparations and substances, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents all for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia, genitourinary conditions, vomiting, allergies, degenerative diseases and central nervous system diseases; excipients, namely, drug delivery agents consisting of compounds that facilitate the delivery a wide range of pharmaceuticals; veterinary pharmaceutical products, preparations and substances, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents all for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia, genitourinary conditions, vomiting, allergies, degenerative diseases and central nervous system diseases; sanitary pharmaceutical products for medical purposes, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia genitourinary conditions, vomiting, allergies, degenerative disease and central nervous system diseases; dietetic substances adopted for medical use; all purpose disinfectants; chemical, biological and biochemical pharmaceutical products for medical and veterinary use, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia genitourinary conditions, vomiting, allergies, degenerative disease and central nervous system diseases Medical studies and clinical studies, namely, scientific research services for medical purposes; research and development of new products for third parties in the medical and pharmaceutical field; engineering services in the medical and pharmaceutical field; chemical research; chemical analyses
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical products, preparations, substances;
excipients; veterinary products; sanitary products for
medical purposes; dietetic substances adapted for medical
use; disinfectants; chemical, biochemical and biological
products for medical and veterinary use. Medical studies and clinical studies (scientific research
services for medical purposes); research and development of
new products (for third parties) in the medical and
pharmaceutical field; engineering services in the medical
and pharmaceutical field; chemical research; chemical
analyses.
69.
GRANULE AND ORALLY DISINTEGRATING TABLET COMPRISING OXYCODONE
The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.
This invention pertains to an orally disintegrating multilayer tablet characterized in that it comprises at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl (meth) acrylate units and optionally a pore-forming agent.
This invention pertains to an orally disintegrating multilayer tablet characterized in that it comprises at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl (meth) acrylate units and optionally a pore-forming agent.
The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.
Water-insoluble matrix tablets which are capable of prolonged release of active principles liable to be diverted for drug addiction purposes, the said active principles being dispersed within a tabletting matrix composed of at least one excipient selected from the group consisting of pH-independent, water-insoluble delay polymers, inorganic excipients and mixtures thereof, and exhibiting a crush resistance of at least 4 MPa.
Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at least 4 MPa.
The invention concerns coated granules comprising (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, said pharmacological active principle being complexed by low cation-exchange resin comprising carboxylic acid groups (COO"), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of said components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules.
The present invention concerns gastroretentive formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent and process for manufacturing said formulation.
The present invention relates to a sublingual coated tablet and to the method for the preparation thereof . The tablet comprises a core devoid of a pharmaceutically active substance, and a coating comprising at least one active substance. The preferred active substance in an opioid analgesic.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical products, preparations, substances;
excipients; veterinary products; sanitary products for
medical purposes; dietetic substances adapted for medical
use; disinfectants; chemical, biochemical and biological
products for medical and veterinary use. Medical studies and clinical studies (scientific research
services for medical purposes); research and development of
new products (for third parties) in the medical and
pharmaceutical field; engineering services in the medical
and pharmaceutical field; chemical research; chemical
analyses.
81.
Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles
The present invention relates to a coated particle of active substance comprising a core, said core comprising the active substance and an acidic compound, said core being coated with a taste masking coating based on a polymer which is soluble at pH of 5 or less, and which is permeable at pH above 5.
A61K 9/54 - Préparations en capsules, p. ex. de gélatine, de chocolat du type à libération prolongée ou discontinue contenant des particules distinctes avec des revêtements de différentes épaisseurs ou de différents matériaux
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical and veterinary products, sanitary
preparations for medical use; dietetic substances adapted
for medical use, disinfectants; rapid disintegration
multiparticulate pills to be taken orally. Engineering services in the medical and pharmaceutical
fields; chemical research; chemical analyses; research and
development in the pharmaceutical field; research and
development in the pharmaceutical field concerning rapid
disintegration multiparticulate pills to be taken orally.
83.
METHOD FOR PREPARING CALIBRATED BIODEGRADABLE MICROSPHERES
The invention relates to a method for preparing monodispersed biodegradable microspheres consisting in a) preparing an emulsion containing at least one polymeric phase and at least one aqueous phase at a viscosity ratio between the dispersed polymeric phase and the aqueous phase ranging from 0.12 to 10, b) exposing the thus obtained emulsion to a controlled laminar shear strength, c) removing a solvent from the polymeric phase and in d) isolating the thus obtained microspheres. The use of the prepared microspheres is also disclosed.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical and veterinary products; sanitary products
for medical purposes; dietetic substances adapted for
medical use; disinfectants. Engineering services in the medical and pharmaceutical
fields; chemical research; chemical analyses; research and
development in the pharmaceutical field.
The invention relates to low-dose tablets obtained by directly compressing microgranules essentially constituted of a neutral support covered by a polymeric layer containing at least one pharmaceutically acceptable polymer and permitting the modified release of active substances in an aqueous medium, to which an active layer containing at least one active substance is applied. The inventive tablets advantageously exhibit a matrix effect similar to that obtained with conventional matrix tablets that depends on the nature of the polymer(s) used for the constitution of the polymeric layer. This matrix effect makes it possible to modify the release profile of the transported active substance based on the type of the polymer used. These tablets are particularly suited for realizing low-dose tablets. The invention also relates to a method for producing these tablets and to the use thereof, particularly for administering active substances in low to very low doses.
The invention relates to a composition comprising a monodispersed lipid phase which is dispersed in a continuous aqueous phase, wherein the lipid phase comprises at least one crystallizable lipid, at least one active ingredient and at least one compound including two chains of fatty acids and one glycol polyethylene chain. The invention also relates to a method for the preparation of said compositions via a simple monodispersed O/W or O/W/O double emulsion.
The subject of the present invention is a new stable herbal drug formulation in the form of sustained-release microgranules containing Gingko Biloba extract as well as the process for preparing it.
The invention is related to the use of a composition of fenofibrate containing micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, said composition containing an amount of fenofibrate greater than or equal to 60% by weight, for the preparation of a medicament for treating hypertriglyceridemias, hypercholesterolemias or hyperlipidemias while reducing the food effect on the bioävailability of fenofibrate. The invention is also related to an immediate release composition in the form of granules comprising : (a) a neutral core; (b) an active layer, wich surrounds the core; and (c)an outer layer; wherein said active layer comprises micronized fenofibrate, a surfactant and a binding cellulose derivative; and wherein said composition has a dissolution profile of less than 10% at 5 minutes and more than 80% at 20 minutes according to the European Pharmacopoeia in a dissolution medium constituted by water with 0.025 M sodium lauryl sulfate.
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development in the pharmaceutical and veterinary fields, in particular into coated microgranules containing an active ingredient, presented in the form of multiparticulate tablets which release the active ingredient they contain in a controlled way over a period of time.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development in the pharmaceutical field, in particular with regard to medicines in dry form consisting of a microcoating directly applied to a raw material.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development for others in the pharmaceutical field namely as regards medicine in dry form consisting of micro-coating directly or indirectly on raw material
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Produits pharmaceutiques, vétérinaires et hygiéniques;
produits diététiques pour enfants et malades; emplâtres,
matériel pour pansements; désinfectants.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical, veterinary and sanitary products; dietetic
substances for medical use; food for infants; plasters,
materials for dressings; material for stopping teeth and
dental wax; disinfectants; pesticides; fungicides;
herbicides.
